UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C., 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
July 7, 2008
Date of Report (Date of earliest event reported)
CELLCYTE GENETICS CORPORATION
(Exact name of registrant as specified in its charter)
Nevada | 000-52238 | 86-1127046 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
1725 220th Street, Suite 103, Bothell Washington | 98021 | |
(Address of principal executive offices) | (Zip Code) |
(425) 483-6101
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
__________
SECTION 8 - OTHER EVENTS
Item 8.01 Other Events
CellCyte Genetics Corporation (the "Company") has determined to reduce the exercise price of certain warrants to purchase common shares of the Company, which warrants were issued on March 30, 2007, as more fully described in a July 7, 2008 letter addressed to the holders of such warrants (which letter is attached hereto as Exhibit 99.1). In addition, a prospectus supplement to the Company's prospectus dated July 11, 2007, as filed with the United States Securities and Exchange Commission, will be filed to disclose the repricing.
Item 9.01 Financial Statements and Exhibits
(a) Financial Statements of Business Acquired
Not applicable.
(b) Pro forma Financial Information
Not applicable.
(c) Shell Company Transaction
Not applicable.
(d) Exhibits
Exhibit | Description |
99.1 | July 7, 2008 Letter from the Company to Holders of Warrants issued on March 30, 2007 |
__________
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CELLCYTE GENETICS CORPORATION | |
Date:July 8, 2008. | /s/ Gary A. Reys |
__________
- 3 -
